Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost–utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study)

INTRODUCTION: There is evidence that low-dose naltrexone (LDN; <5.0 mg/day) reduces pain and improves the quality of life of people with fibromyalgia syndrome (FMS). However, no randomised controlled trials with long-term follow-ups have been carried out. The INNOVA study will evaluate the add-on...

Descripción completa

Detalles Bibliográficos
Autores principales: Colomer-Carbonell, Ariadna, Sanabria-Mazo, Juan P, Hernández-Negrín, Halbert, Borràs, Xavier, Suso-Ribera, Carlos, García-Palacios, Azucena, Muchart, Jordi, Munuera, Josep, D'Amico, Francesco, Maes, Michael, Younger, Jarred W, Feliu-Soler, Albert, Rozadilla-Sacanell, Antoni, Luciano, Juan V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Rheumatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739052/
https://www.ncbi.nlm.nih.gov/pubmed/34992118
http://dx.doi.org/10.1136/bmjopen-2021-055351

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739052/
https://www.ncbi.nlm.nih.gov/pubmed/34992118
http://dx.doi.org/10.1136/bmjopen-2021-055351

Ejemplares similares